Literature DB >> 22623796

Human papillomavirus type 8 E6 oncoprotein inhibits transcription of the PDZ protein syntenin-2.

Daliborka Lazić1, Martin Hufbauer, Paola Zigrino, Stephanie Buchholz, Siamaque Kazem, Mariet C W Feltkamp, Cornelia Mauch, Gertrud Steger, Herbert Pfister, Baki Akgül.   

Abstract

The E6 proteins from high-risk alpha human papillomavirus (HPV) types (e.g., HPV16) are characterized by the presence of a PDZ-binding motif through which they interact with a number of cellular PDZ domain-containing substrates and cooperate in their degradation. The ability of these E6 proteins to bind to PDZ domain proteins correlates with the oncogenic potential of the virus. The E6 proteins of oncogenic HPV from the genus Betapapillomavirus (betaPV, e.g., HPV8) do not encode a PDZ-binding motif. We found that the PDZ domain protein syntenin-2 is transcriptionally downregulated in primary human epidermal keratinocytes (PHEK) by HPV8 E6. The mRNA levels of the known HPV16 E6 PDZ protein targets Dlg, Scribble, Magi-1, Magi-3, PSD95, and Mupp1 were not changed by HPV8 E6. Decreased protein levels of syntenin-2 were observed in cell extracts from PHEK expressing HPV5, -8, -16, -20, and -38 E6 but not in HPV1 and -4 E6-positive keratinocytes. Surprisingly, HPV16 E6 also repressed transcription of syntenin-2 but with a much lower efficiency than HPV8 E6. In healthy human skin, syntenin-2 expression is localized in suprabasal epidermal layers. In organotypic skin cultures, the differentiation-dependent expression of syntenin-2 was absent in HPV8 E6- and E6E7-expressing cells. In basal cell carcinomas of the skin, syntenin-2 was not detectable, whereas in squamous cell carcinomas, expression was located in differentiated areas. Short hairpin RNA-mediated knockdown of syntenin-2 led to an inhibition of differentiation and an increase in the proliferation capacity in PHEK. These results identified syntenin-2 as the first PDZ domain protein controlled by HPV8 and HPV16 at the mRNA level.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623796      PMCID: PMC3421679          DOI: 10.1128/JVI.00132-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  The human papillomavirus E6 protein and its contribution to malignant progression.

Authors:  F Mantovani; L Banks
Journal:  Oncogene       Date:  2001-11-26       Impact factor: 9.867

2.  The neural cell recognition molecule neurofascin interacts with syntenin-1 but not with syntenin-2, both of which reveal self-associating activity.

Authors:  M Koroll; F G Rathjen; H Volkmer
Journal:  J Biol Chem       Date:  2001-01-04       Impact factor: 5.157

3.  Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.

Authors:  M A Dickson; W C Hahn; Y Ino; V Ronfard; J Y Wu; R A Weinberg; D N Louis; F P Li; J G Rheinwald
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

4.  Transduction of the E6 and E7 genes of epidermodysplasia-verruciformis-associated human papillomaviruses alters human keratinocyte growth and differentiation in organotypic cultures.

Authors:  I L Boxman; L H Mulder; F Noya; V de Waard; S Gibbs; T R Broker; F ten Kate; L T Chow; J ter Schegget
Journal:  J Invest Dermatol       Date:  2001-12       Impact factor: 8.551

5.  Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins.

Authors:  S Jackson; C Harwood; M Thomas; L Banks; A Storey
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

Review 6.  Papillomaviruses and cancer: from basic studies to clinical application.

Authors:  Harald zur Hausen
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

Review 7.  Human papillomavirus immortalization and transformation functions.

Authors:  Karl Münger; Peter M Howley
Journal:  Virus Res       Date:  2002-11       Impact factor: 3.303

8.  High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis.

Authors:  Valentina Dell'Oste; Barbara Azzimonti; Marco De Andrea; Michele Mondini; Elisa Zavattaro; Giorgio Leigheb; Sönke J Weissenborn; Herbert Pfister; Kristina M Michael; Tim Waterboer; Michael Pawlita; Ada Amantea; Santo Landolfo; Marisa Gariglio
Journal:  J Invest Dermatol       Date:  2008-10-16       Impact factor: 8.551

9.  High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent population.

Authors:  Herbert Pfister; Pawel G Fuchs; Slawomir Majewski; Stefania Jablonska; Iwona Pniewska; Magdalena Malejczyk
Journal:  Arch Dermatol Res       Date:  2003-11-15       Impact factor: 3.017

Review 10.  Chapter 8: Human papillomavirus and skin cancer.

Authors:  Herbert Pfister
Journal:  J Natl Cancer Inst Monogr       Date:  2003
View more
  12 in total

1.  Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity.

Authors:  Elizabeth A White; Rebecca E Kramer; Min Jie Alvin Tan; Sebastian D Hayes; J Wade Harper; Peter M Howley
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

2.  Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: a population-based study.

Authors:  Shohreh F Farzan; Tim Waterboer; Jiang Gui; Heather H Nelson; Zhongze Li; Kristina M Michael; Ann E Perry; Steven K Spencer; Eugene Demidenko; Adele C Green; Michael Pawlita; Margaret R Karagas
Journal:  Int J Cancer       Date:  2013-04-22       Impact factor: 7.396

3.  Roles of the PDZ domain-binding motif of the human papillomavirus type 16 E6 on the immortalization and differentiation of primary human foreskin keratinocytes.

Authors:  Moonju Choi; Sungjin Lee; Taekyu Choi; Choongho Lee
Journal:  Virus Genes       Date:  2013-11-29       Impact factor: 2.332

Review 4.  Proteomic approaches to the study of papillomavirus-host interactions.

Authors:  Elizabeth A White; Peter M Howley
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

5.  Discovery and confirmation of ligand binding specificities of the Schistosoma japonicum polarity protein Scribble.

Authors:  Pengfei Cai; Yi Mu; Xianyu Piao; Nan Hou; Shuai Liu; Youhe Gao; Heng Wang; Qijun Chen
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

6.  Immortalized N/TERT keratinocytes as an alternative cell source in 3D human epidermal models.

Authors:  Jos P H Smits; Hanna Niehues; Gijs Rikken; Ivonne M J J van Vlijmen-Willems; Guillaume W H J F van de Zande; Patrick L J M Zeeuwen; Joost Schalkwijk; Ellen H van den Bogaard
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

Review 7.  Viral Interactions with PDZ Domain-Containing Proteins-An Oncogenic Trait?

Authors:  Claire D James; Sally Roberts
Journal:  Pathogens       Date:  2016-01-18

8.  The interplay of UV and cutaneous papillomavirus infection in skin cancer development.

Authors:  Daniel Hasche; Sonja Stephan; Ilona Braspenning-Wesch; Julita Mikulec; Martina Niebler; Hermann-Josef Gröne; Christa Flechtenmacher; Baki Akgül; Frank Rösl; Sabrina E Vinzón
Journal:  PLoS Pathog       Date:  2017-11-30       Impact factor: 6.823

9.  Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis.

Authors:  Swadesh K Das; Chunqing Guo; Anjan K Pradhan; Praveen Bhoopathi; Sarmistha Talukdar; Xue-Ning Shen; Luni Emdad; Mark A Subler; Jolene J Windle; Devanand Sarkar; Xiang-Yang Wang; Paul B Fisher
Journal:  Oncotarget       Date:  2016-07-26

10.  HPV8-E6 Interferes with Syntenin-2 Expression through Deregulation of Differentiation, Methylation and Phosphatidylinositide-Kinase Dependent Mechanisms.

Authors:  Benjamin Marx; Daliborka Miller-Lazic; John Doorbar; Slawomir Majewski; Kay Hofmann; Martin Hufbauer; Baki Akgül
Journal:  Front Microbiol       Date:  2017-09-08       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.